Online inquiry

IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14779MR)

This product GTTS-WQ14779MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14779MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4344MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ6446MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ7358MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ149MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ3119MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ3967MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ643MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ5821MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW